Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX) announced top line results from its Phase 1(b) double-blind, placebo controlled safety and tolerance study ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE